TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06925321: A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Sponsor: Basilea Pharmaceutica · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 234 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,214,596

Rescue Site Savings

+$2,129,148

Unlock Full NCT06925321 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06925321 Rescue Dossier →